A Phase 3 Randomized Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1 and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

Brief description of study

This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study of pembrolizumab + lenvatinib in cisplatin-ineligible participants whose tumors express PD-L1 (CPS =10), and in participants ineligible for any platinum-containing chemotherapy, with advanced/unresectable or metastatic UC. This Phase 3 study will be conducted in participants with measurable disease who provide tumor tissue (newly obtained or archival formalin-fixed paraffin-embedded [FFPE] tumor biopsy) for determination of PD-L1 expression, as assessed with the diagnostic IHC 22C3 pharmDx at the central laboratory.

Clinical Study Identifier: s18-01918
ClinicalTrials.gov Identifier: NCT03898180
Principal Investigator: Arjun Vasant Balar.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.